Less Ads, More Data, More Tools Register for FREE

FTSE 100 lags European peers as GSK, stronger pound weigh

Mon, 07th Nov 2022 17:46

FTSE 100 down 0.5%, FTSE 250 adds 1.2%

*

GSK down on failed late-stage study

*

Joules falls on suffering sales

Nov 7 (Reuters) - Britain's FTSE 100 slipped on Monday, lagging its European peers, as a stronger pound and a fall in the shares of drugmaker GSK offset optimism over China potentially easing its zero COVID-19 policy despite denials from Beijing officials.

The blue-chip FTSE 100 slipped 0.5% after hitting an a more than seven-week high on Friday, driven by gains in China-exposed miners. The wider European STOXX 600 index closed up 0.3%.

Among the biggest drags on FTSE 100 was GSK Plc, down 4.7%, after it said its blood cancer drug Blenrep failed the main goal of a late-stage study. The wider pharma index was down 1.6%.

Meanwhile, the pound gained nearly 0.9%, denting shares of dollar earners such as AstraZeneca and Diageo .

However, the mid-cap FTSE 250 rose 1.2%, mirroring a risk-on sentiment in global stocks despite mixed signals about China possibly reversing its zero COVID policy.

"The latest U.S. jobs report and a denial of any easing of China's zero COVID measures have failed to dent market optimism it seems, a sign perhaps that the buyers have control for the time being," said Chris Beauchamp, chief market analyst at online trading platform IG.

The focus this week will be on a preliminary reading of Britain's third-quarter GDP on Friday and the budget plan next week. The markets took comfort last week as the Bank of England indicated that interest rates would increase at a slower pace than current market expectations.

Shares of Joules Group plunged 23.5% after the struggling British fashion retailer said its sales in the 11 weeks to Oct. 30 were lower than expectations as it discusses a potential cornerstone investment in an equity raise.

Flutter Entertainment jumped 2.7% after it said that the arbitrator was in favour of the firm's valuation of FanDuel at $20 billion, ending its legal battle with FOX corporation. (Reporting by Johann M Cherian and Shruthi Shankar in Bengaluru; Editing by Sherry Jacob-Phillips, Shinjini Ganguli and Alison Williams)

Related Shares

More News
11 Jun 2024 14:31

Zantac litigation fears overdone at GSK, says Shore Capital

(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but th...

11 Jun 2024 09:32

TOP NEWS: GSK takes first steps to appeal Zantac ruling in Delaware

(Alliance News) - GSK PLC on Tuesday said it has taken the first steps to seek appeal of a ruling by the Delaware Superior Court in regard to its disc...

11 Jun 2024 09:12

LONDON MARKET OPEN: FTSE 100 up; UK unemployment rises to 4.4%

(Alliance News) - Stock prices in London opened higher on Tuesday, after a difficult day for markets on Monday amid the EU election fallout.

11 Jun 2024 07:52

LONDON BRIEFING: FTSE 100 called up despite unemployment rise

(Alliance News) - The FTSE 100 in London was called to open higher on Tuesday, after data showed that unemployment in the UK unexpectedly rose.

11 Jun 2024 07:22

GSK launches appeal to recent Zantac ruling

(Sharecast News) - GSK has started the process of appealing a recent decision by the Delaware Superior Court regarding the ongoing Zantac, or ranitidi...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.